Related Experiment Videos
Systemic tumor suppression by the proapoptotic gene bik.
Yiyu Zou1, Hua Peng, Binhua Zhou
1Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer Research
|January 10, 2002
Summary
A novel systemic gene therapy using SN (SN) and bik gene effectively treats metastatic breast cancer. This approach demonstrated superior transfection efficiency and significant tumor reduction in preclinical models.
Area of Science:
- Oncology
- Gene Therapy
- Nanotechnology
Background:
- Metastatic breast cancer necessitates effective systemic treatments.
- Current nonviral gene delivery systems face challenges in efficiency, especially in serum conditions.
Purpose of the Study:
- To develop and evaluate a novel systemic gene therapy for breast cancer.
- To assess the efficacy of a nonviral gene delivery system (SN) combined with a proapoptotic gene (bik).
Main Methods:
- Development of a nonviral gene delivery system (SN).
- In vitro transfection efficiency assessment of SN-SN carrying a reporter gene compared to Fugene-6 and Lipofectamine.
- In vitro apoptosis induction in breast cancer cell lines by SN-bik.
- In vivo efficacy study in nude mice with orthotopic breast cancer xenografts.
Main Results:
- SN exhibited 5-10 times higher transfection efficiency than Fugene-6 and Lipofectamine in serum.
- SN-bik significantly induced apoptosis in breast cancer cell lines and orthotopic tumors.
- Systemic administration of SN-bik inhibited tumor growth and metastasis in mice.
- SN-bik treatment prolonged the survival of tumor-bearing mice.
Conclusions:
- The SN-bik gene complex represents a promising systemic gene therapy for breast cancer.
- This approach shows potential for reducing tumor burden and metastasis.
- Further development of SN-bik as a therapeutic agent for cancer is warranted.